⚠️ FDA Failures and GLP-1 Compounding Risks
“FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a surge in unregulated “knock-offs” from compounding pharmacies, even after the shortages ended. The report details the inherent risks of compounded drugs, […]
Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation
GLP-1 diabetes drugs likely trump metformin for curbing dementia risk in type 2 diabetes, study finds
GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.
Ozempic-like fat jabs are BETTER than common drug at reducing dementia risk, study finds
FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, say scientists. While both medications demonstrate neuroprotective properties, no comparison has been made up until now. GettyGLP-1 receptor agonists have recently gained popularity as a weight loss medication[/caption] Metformin is generally the first-line medication […]
‘Ozempic Teeth:’ Another Effect of GLP-1 Agonists?
(MedPage Today) — Welcome to Culture Clinic, MedPage Today’s collaboration with Northwell Health to offer a healthcare professional’s take on the latest viral medical topics. Cases of “Ozempic mouth” and “Ozempic teeth” have recently been described…
The ultimate gut-healthy grocery list to boost Akkermansia and Clostridium – the natural path to glp-1
(NaturalNews) Imagine walking through the aisles of your local grocery store, armed with the knowledge that the items you pick can not only nourish your body but al…
Risk for dementia, ischemic stroke, mortality lower with GLP-1 receptor agonists in type 2 diabetes, obesity
For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs, according to a study published online July 15 in JAMA Network Open.
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 — For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs…
BRING IT ON HOME: AstraZeneca plans to invest $50 billion in America for medicines manufacturing and
BRING IT ON HOME: AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D. AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and […]
GLP-1 Drugs Fail to Provide Key Weight-Loss Benefit
University of Virginia Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in heart and lung function essential for…